Global RNA-based Biopharmaceuticals Market Size By Type (Therapeutics, Vaccines), By Application (Cancer, Diabetes), By Region, And Segment Forecasts, 2023 to 2032

The Global RNA-based Biopharmaceuticals Market was valued at USD 14.7 billion in 2023 and is expected to reach USD 41.6 billion by 2031, growing at a CAGR of 14.2% during the forecast period from 2023 to 2031. The surge in RNA-based therapeutics, particularly mRNA technologies, has revolutionized the pharmaceutical landscape. Following the success of mRNA vaccines, RNA modalities such as siRNA, antisense RNA, and RNA aptamers are being actively developed for conditions ranging from infectious diseases to cancer and rare genetic disorders. Increasing R&D investments, technological advancements in drug delivery, and favorable regulatory frameworks are major contributors to market expansion.

Drivers:

1. Post-COVID RNA Innovation Surge:

The unprecedented success of mRNA vaccines for COVID-19 accelerated funding, partnerships, and clinical pipelines in RNA therapies. This momentum is expected to continue, fueling rapid innovation across therapeutic areas.

2. Advancements in RNA Delivery Platforms:

Efficient delivery systems such as lipid nanoparticles (LNPs) and novel carriers have significantly improved the stability and efficacy of RNA-based drugs, addressing earlier limitations in drug transport and targeting.

3. Growing Pipeline and Clinical Trials:

Numerous RNA-based drugs are in various stages of clinical trials, especially for oncology, rare diseases, and immunological disorders, boosting market prospects.

Restraints:

1. High Development and Manufacturing Costs:

Complex synthesis processes, cold-chain requirements, and specialized facilities make RNA-based drugs expensive to develop and produce.

2. Safety and Immune Response Concerns:

RNA-based therapeutics can trigger unintended immune reactions. Ensuring safety, especially in repeat dosing, remains a regulatory and clinical challenge.

Opportunity:

1. Personalized and Precision Medicine:

RNA-based biopharmaceuticals offer unmatched flexibility in designing patient-specific therapies, opening up significant opportunities in personalized medicine.

2. Expansion in Emerging Markets:

Growing healthcare investments in Asia-Pacific, Latin America, and the Middle East create favorable environments for introducing advanced RNA therapies.

Market by System Type Insights:

Based on system type, mRNA-based therapeutics held the largest share in 2023. Their successful deployment in infectious disease prevention has paved the way for applications in cancer immunotherapy and protein replacement therapy. siRNA-based therapies are also gaining traction, particularly for rare diseases and metabolic conditions, and are projected to grow at the fastest CAGR during the forecast period.

Market by End-use Insights:

By end-use, the biotechnology and pharmaceutical companies segment accounted for the largest market share in 2023 due to their central role in R&D, clinical trials, and commercial distribution of RNA-based drugs. Academic and research institutes are also crucial contributors, particularly in early-stage discovery and innovation partnerships.

Market by Regional Insights:

North America dominated the RNA-based biopharmaceuticals market in 2023, driven by robust clinical pipelines, strong funding ecosystems, and early adoption of novel therapies. However, Asia-Pacific is anticipated to witness the fastest growth through 2031, fueled by increased investment in biotech infrastructure and rising disease awareness in countries such as China, India, and South Korea.

Competitive Scenario:

Key players in the market include Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals, CureVac AG, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Translate Bio (Sanofi), Sarepta Therapeutics, Silence Therapeutics, and Arcturus Therapeutics. These companies are leveraging strategic collaborations, expanding their manufacturing capacities, and accelerating clinical pipelines to strengthen their positions.

Scope of Work – Global RNA-based Biopharmaceuticals Market

Key Market Developments:

2023: Moderna initiated Phase III trials for an mRNA-based cancer vaccine targeting melanoma.

2024: Alnylam Pharmaceuticals received expanded FDA approval for an siRNA drug for polyneuropathy in hereditary ATTR amyloidosis.

2025: BioNTech announced a multi-billion dollar expansion into Asia-Pacific with a new mRNA manufacturing facility in Singapore.

2025: Sanofi integrated Translate Bio's RNA platform into its global vaccine and rare disease divisions, streamlining R&D.

FAQs:

1) What is the current market size of the Global RNA-based Biopharmaceuticals Market?

The market size was valued at USD 14.7 billion in 2023.

2) What is the major growth driver of the Global RNA-based Biopharmaceuticals Market?

The major growth driver is the continued innovation and application of mRNA and siRNA therapies, especially post-COVID-19.

3) Which is the largest region during the forecast period in the Global RNA-based Biopharmaceuticals Market?

North America holds the largest market share, while Asia-Pacific is the fastest-growing region.

4) Which segment accounted for the largest market share in Global RNA-based Biopharmaceuticals Market?

The mRNA-based therapeutics segment held the largest share in 2023.

5) Who are the key market players in the Global RNA-based Biopharmaceuticals Market?

Key players include Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals, CureVac AG, and Ionis Pharmaceuticals.